Setonda

Setonda is a biotechnology company focused on developing small molecule inhibitors of the mTORC1 pathway for the treatment of neurological disorders. The company's primary focus is on genetic forms of epilepsy, particularly those caused by mutations in the DEPDC5 gene, which lead to hyperactivation of mTORC1. By targeting the underlying nutrient-sensing and signaling mechanisms, Setonda aims to provide precision medicine for patients with treatment-resistant focal epilepsies. The company was founded based on the pioneering research of David Sabatini into the mTOR pathway. Setonda represents a commercial effort to translate basic science findings regarding mTOR regulation into therapeutic interventions for rare and severe neurological conditions.